ࡱ >
\ p None B a = c @ = Z ?N*8 X" 1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial General ` b Table_1 ` M Subject Treatment( Baseline IU/ml (log10)- Study day sequenced post-viral rebound( Estimated number of input genomes" Position 415 amino acid (%)" Position 417 amino acid (%) A MBL-HCV1 6.7 14 2,664,824 D (78.5) N (78.8) N (20.8) S (20.5) B 6.1 27,214 K (97.1) N (99.0) N (1.7) C 7.2 32,037 D (56.0) N (85.6) N (39.7) S (12.7) K (2.6) D 4.5 56 48,210 S (78.4) K (20.2) N (21.1) E 6.0 28 32,196 K (94.2) N (97.9) N (2.7) F 42 251,910 N (69.5) N (61.5) S (27.1) S (36.5) D (1.2) G Placebo 6.6 7 1,698,789 N (99.1) N (98.8) H 5.5 25,752 N (95.9) N (96.7) I 21 575,572 N (98.6) J 5.1w 21* S (98.7) K 5.6 2,434,095 N (98.9) N (99.3)
d MbP?_ % * + &P &F